NEW YORK (GenomeWeb) – In a study appearing online today in Cancer Immunology Research, investigators at Johns Hopkins University School of Medicine described differences in metabolic gene expression that coincided with response to Bristol-Myers Squibb's anti-PD-1 drug Opdivo (nivolumab) in individuals with PD-L1-positive renal cell carcinoma (RCC) kidney cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.